Side-by-side · Research reference

BPC-157vsLivagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED9/53 cited

BAnimal-StrongHUMAN-REVIEWED20/32 cited

BPC-157

Stable Gastric Pentadecapeptide · Healing

250–500 mcgDaily doseHwang 2016

Phase 2Evidence levelHwang 2016 Sikiric 2018

~30 minHalf-life (est.)

SQ or IM · Local · Once or twice daily

Livagen

Khavinson Bioregulator · Hepatoprotective Tetrapeptide

50%Dipeptidase inhibitionTimofeeva 2005

Oral / SQRoutes tested

LiverTarget tissueKhavinson 2001

Oral or SQ · Tissue-specific to liver

01Mechanism of Action

Parameter

BPC-157

Livagen

Primary target

VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2011 Sikiric 2018

Hepatocyte protein synthesis machineryBrodskiĭ 2001

Pathway

Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2011

Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001 Khavinson 2001

Downstream effect

Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018

Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes

Feedback intact?

No known endogenous receptor; mechanism still under investigation

—

Origin

Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018

Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)

Antibody development

—

02Dosage Protocols

Parameter

BPC-157

Livagen

Standard dose

250–500 mcg / dayHwang 2016

Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.

—

Frequency

Once or twice daily

Split dosing reported anecdotally for chronic injury.

—

Lower / starter dose

200 mcg / day

Conservative starter for new users.

—

Evidence basis

Animal-strong + Phase 2 clinicalSikiric 2018 Hwang 2016

Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005 Brodskiĭ 2001 Khavinson 2002

Duration

2–4 weeks (acute injury); 4–8 weeks (chronic)

Anecdotal; no long-term human safety data.

—

Reconstitution

Bacteriostatic water, 1–2 mL

—

Timing

Local SQ to injury site preferred (anecdotal)

Systemic SQ also used; oral bioavailability shown in animal studies.

—

Half-life

~30 min plasma (estimated)

Tissue half-life longer; mechanism may explain durable effect.

—

Animal dose (oral)

—

Not specified in abstracts; 2-week administration protocolTimofeeva 2005

Per os administration in rats.

Duration (experimental)

—

2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005 Brodskiĭ 2001

Route

—

Oral or subcutaneous

Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005

Human data

—

None in provided literature

04Side Effects & Safety

Parameter

BPC-157

Livagen

Injection site reaction

Mild irritation (anecdotal)

—

GI symptoms

None reported in PL-14736 Phase 2

—

Cardiovascular

Not reported

—

Cancer risk

Theoretical concern via VEGF angiogenesis pathwaySikiric 2018

—

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid — insufficient safety data

—

Long-term safety

Unknown beyond Phase 2 trial duration

—

Drug interactions

None established

—

Reported adverse effects

—

None documented in animal studies

Human safety data

—

No human trials in provided literature

Peptide hydrolysis

—

Weakly hydrolyzed; minimal breakdown by intestinal enzymesTimofeeva 2005

Absolute Contraindications

BPC-157

·Pregnancy / breastfeeding
·Known active malignancy (theoretical VEGF concern)

Livagen

—

Relative Contraindications

BPC-157

·History of cancer
·Concurrent VEGF inhibitor therapy (theoretical)
·Acute thrombotic events

Livagen

—

05Administration Protocol

Parameter

BPC-157

Livagen

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.

Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005 Khavinson 2001

2. Injection site

Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.

No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005

3. Timing

No strict timing requirement. Most users dose once or twice daily, often morning + evening.

Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.

—

5. Needle

27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.

—

06Stack Synergy

BPC-157

+ TB-500

Strong

View TB-500 →

BPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.

BPC-157: 250–500 mcg SQ · daily
TB-500: 2 mg SQ · 2× per week
Primary benefit: Tendon/ligament/muscle repair via complementary angiogenesis + migration

Livagen

— no documented stacks